MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company
23 Fevereiro 2023 - 3:22PM
Business Wire
Institutional Shareholder Services (ISS) awarded MedinCell a
“Prime” Environmental, Social, and Governance (ESG) rating.
Rating places MedinCell among the top 10% in the
Pharmaceuticals & Biotechnology sector.
ISS, one of the world’s leading ratings agencies for
sustainable investments, provides a highly relevant, material
assessment of ESG performance to investors.
MedinCell is a pharmaceutical technology company with 150
employees from 30 nationalities, all shareholders.
The first product based on MedinCell’s long-acting injectable
technology should get FDA market approval by April 2023, two
additional products are in phase 3, and a pipe of other products
follows.
Access here the complete press
release
MedinCell (Paris:MEDCL):
“This recognition is a tribute to MedinCell efforts and
performance.” said Christophe Douat, CEO of MedinCell. “Strong ESG
performance is an increasingly important factor in attracting
investors and the Prime status received from ISS ESG is a valuable
guide for those seeking to identify companies that are driving
positive change. We have always considered that our sustainable
company model is inseparable from our raison d’être.”
MedinCell began to formalize its corporate and social
responsibility with the inclusion of its raison d’être in its
statutes in 2019: Our mission is to contribute to the improvement
and protection of the health of populations across the world. The
fair sharing of the value created with all our employees is the
foundation of our business model. The sustainability of MedinCell
is an essential condition for achieving our objectives. In 2022,
the Company established an ESG committee at its board. Other
achievements include the embedment of ESG culture and the
implementation of quantitative ESG objectives.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230223005861/en/
MedinCell David Heuzé Head of Communications
david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Louis-Victor Delouvrier/Alban Dufumier Investor Relations
medincell@newcap.eu +33 (0)1 44 71 94 94
NewCap Nicolas Merigeau Media Relations medincell@newcap.eu +33
(0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
